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Abstract Both p16INK4 and p21Waf1 are very important nega-
tive regulators of the cell cycle. In this study we examined the
e¡ects of p21Waf1 on the transcription of p16INK4. We deter-
mined that p21Waf1 can activate the transcription of p16INK4,
and that this e¡ect is GC-box dependent. We also found that
the transcription factor Sp1 plays a key role in this event. Up-
regulation of Sp1 contributes to the transcriptional activation
and protein level of p16INK4 mediated by p21Waf1, and is a
potential point of cooperation between the p16/pRb and p14
(ARF)/p53 tumor suppressor pathways.
1 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
p16INK4 gene is a tumor suppressor involved in regulating
cell cycle checkpoints. It is frequently inactivated by methyl-
ation or mutation [1]. The p16INK4 protein binds speci¢cally
to and inhibits the cyclin-dependent kinases 4/6 (CDK4/6),
which regulate cell cycle progression in G1 through phosphor-
ylation of the retinoblastoma protein (pRb) [2,3]. p21Waf1 is
one key regulator of the cell cycle and acts as a universal
inhibitor of CDKs [4]. It plays an important role in cellular
senescence, proliferation, di¡erentiation, as well as DNA
damage and repair [5^7]. Signi¢cant data have shown that
p16INK4 and p21Waf1 have very similar biological functions
and it has been reported that p21Waf1 is an e¡ector for
p16INK4 [8]. However, much less is known about the e¡ect
of p21Waf1 on the expression of p16INK4, especially with re-
gards to transcriptional regulation. Whether they can in£u-
ence each other and whether there is crosstalk between these
two pathways (p16/pRb and ARF/p53) remain open ques-
tions. In this report, we present our study of the in£uence
of p21Waf1 on the expression of p16INK4 at the transcription
level.
2. Materials and methods
2.1. Plasmids
The p21Waf1 cDNA was a gift from Dr. David Beach (Howard
Hughes Medical Institute, Cold Spring Harbor, NY, USA). The
full-length 2.1-kb p21Waf1 cDNA was inserted, in both antisense and
sense orientation, into the cloning site of the retroviral vector pDOR-
neo [9]. The pDOR-neo vector without an insert served as the control
[10]. The Sp1 cDNA expression vector was a gift from Dr. Robert
Tjian (University of California, Berkeley, CA, USA) and the Sp3
expression vector was a gift from Dr. G. Suske (IMT, Marburg,
Germany). The pCMV vector without an insert also served as the
control. The plasmids pSIR-0-EGFP, pSIR-620-EGFP and pSIR-
870-EGFP acted as the reporter reconstructions, into which the di¡er-
ent fragments of the promoter of p16INK4 were inserted (pSIR-0-
EGFP, no fragment of the promoter was inserted; pSIR-620-EGFP,
620 bp upstream of ATG was inserted; pSIR-870-EGFP, 870 bp up-
stream of ATG was inserted), all of them were gifts from Dr. W.
Wang in our lab [11].
2.2. Cell culture
A human epithelioid cervical carcinoma cell line (HeLa cells) was
cultured in Dulbecco’s modi¢ed Eagle’s medium (DMEM). Stable
transfection using 1 Wg pDOR-p21Waf1 was performed with lipofect-
amine (Invitrogen). 400 Wg/ml G418 was added into the medium for
drug selection 48 h after transfection, until the stable positive cell
clones were obtained. Mithramycin A (Sigma) (50, 100 nM) was
added to the cells 24 h before harvest [12,13].
2.3. Construction of promoter-Luc constructs and luciferase activity
assay
To make pGL3-870, an 870-bp 5P-fragment of human p16INK4 pro-
moter was digested with XhoI and HindIII from pSIR-870-EGFP, and
then inserted into the same sites in pGL3-basic (Promega). pGL3-620
was generated with a 620-bp 5P-fragment of human p16INK4 promoter
digested with XhoI and HindIII from pSIR-620-EGFP. A 126-bp 5P-
fragment of human p16INK4 promoter was cloned into the SacI site of
the same vector by site-directed mutagenesis of the 3620-bp p16INK4
promoter (Quickchange1 site-directed mutagenesis methods, Strata-
gene). A synthetic double-strand oligonucleotide was used to create a
new SacI restriction site at position 3126 bp (5P-GGGTCGG-
AGGGAGCTCTTCCGCCAGCAC-3P). Mutation of Sp family bind-
ing sites was performed with the same kit as mentioned above. They
were called 3449 m (5P-GGGGCGGATT-3P to 5P-GGGGCaGATc-
3P), 3459m (5P-AAACGGGGCGGGG-3P to 5P-AAACGGatCcG
GG-3P) and dm (double mutation 5P-AAACGGGGCGGGGGCG-
GATT-3P to 5P-AAACGGatCcGGGGCaGATc-3P). All plasmids
were puri¢ed with QIAGEN Plasmid Midi Kits (Qiagen). Transfec-
tions were performed in 24-well plates using lipofectamine 2000 (In-
vitrogen). HeLa cells were harvested 48 h post-transfection and as-
sayed for luciferase and L-galactosidase activities according to
standard procedures. All transfections were carried out in triplicate,
and all experiments were performed twice for con¢rmation.
2.4. Western blot
Cell extracts were prepared following standard procedures. Brie£y,
three to ¢ve volumes of lysis bu¡er (50 mM Tris^HCl, pH 7.4, 0.25 M
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NaCl, 0.1% Triton X-100, 1 mM ethylenediamine tetraacetic acid
(EDTA), 50 mM NaF, 1 mM dithiothreitol (DTT), 0.1 mM Na3VO4)
were added to a cell pellet. Then the following protease inhibitors
were added: 0.1 mM phenylmethylsulfonyl £uoride (PMSF), 1 Wg/
ml leupeptin, 1 Wg/ml aprotinin. After incubation on ice for 30 min,
samples were centrifuged at 14 000 rpm for 5 min at 4‡C to recover
the supernatant. After proteins were electrophoresed in a 15% (for Id1
and p16) or 8% (for Sp1, Sp3, L-actin and E47) denaturing polyac-
rylamide gel and transferred to a polyvinylidene di£uoride (PVDF)
membrane, the membrane was blocked in 5% non-fat milk^Tris-bu¡-
ered saline (TBS)^0.25% Tween 20 for 1 h and incubated with the
primary antibody in TBS^0.25% Tween 20 for 1 h at room temper-
ature. Complexes were detected with horseradish peroxidase-linked
secondary antibody and enhanced chemiluminescence (SuperSignal,
Pierce). The primary and secondary antibodies used in this study
were all from Santa Cruz Biotechnology (Santa Cruz).
2.5. Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared from cells, following the previous
described procedures [11]. Sp1 and Sp3 binding probes were annealed
by heating the following single-stranded oligonucleotides: forward: 5P-
AAGGAAACGGGGCGGGGGCGGATTTCTTTTTAACAGAG-3P
and reverse: 5P-CTCTGTTAAAAAGAAATCCGCCCCCGCCCCG-
TTTCCTTCC-3P. Probes were labeled using Klenow at room temper-
ature for 15 min. The labeled probe was puri¢ed with QIAquick Nu-
cleotide Removal Kit (Qiagen). 32P-labeled probe DNA (30 000^
50 000 cpm) was incubated in DNA binding bu¡er (10 mM Tris^
HCl, pH 7.5, 2.5 mM MgCl2, 50 mM KCl, 1 mM DTT, 10% glycerol,
and 25 Wg/ml poly dI:dC) for 20 min at room temperature. DNA^
protein complexes were analyzed on 6% polyacrylamide gels. Gels
were dried and exposed to X-ray ¢lm for 24 h.
3. Results
3.1. p21Waf1 activates the expression of the p16INK4 in both the
promoter-luc constructs and the protein in HeLa cells
Transient cotransfection studies with pGL3-870 and the
p21Waf1 expression vector were performed in HeLa cells (it
has previously been shown that fragments longer than 870
bp have no additional promoter activity [14]). The results
showed that p21Waf1 augmented the p16INK4 promoter activity
(Fig. 1A). The same tendency was shown in the stably trans-
fected cells using the EGFP as reporter gene (Fig. 1B), the
percentage of the positive cells is 10% higher than the control.
To determine the location of the DNA sequences associated
with the activation, the p21Waf1 vector was cotransfected with
shorter sequences (620 and 126 bp) of the p16INK4 promoter
DNA. Marked activation was found with the 620 bp con-
struct (it is nearly 4-fold). The promoter region 3127^3620
bp seemed particularly important (Fig. 1A), suggesting that
p21Waf1 interacts with p16INK4 regulatory region through cer-
tain transcriptional regulators whose binding sites are located
within this region.
To further demonstrate that whether the endogenous
p16INK4 could be upregulated by p21Waf1, Western blot was
used to detect the protein level of p16INK4 after the transfec-
tion of p21Waf1-sense and p21Waf1-antisense. The expression of
p16INK4 showed a slight increase of nearly 20% in the p21Waf1-
sense group and a dramatic decrease of nearly 50% in the
p21Waf1-antisense group, through the analysis of density ver-
sus control (Fig. 1C and D).
We then examined the character of the sequence from 3127
to 3620 bp of p16INK4 promoter in more detail. This region
contains three GC-boxes (GGGCGG), two E-boxes
(CANNTG) and some other regulatory elements. Among
these elements, the GC-box is a prominent feature of the
p16INK4 promoter. To determine whether the e¡ect of
Fig. 1. The e¡ect of transcriptional activation of p16INK4 by p21Waf1
A: E¡ect of p21Waf1 on expression of the p16INK4 promoter-luc con-
structs (126, 620 and 870 bp). Various deletions of the p16INK4 con-
structs (0.4 Wg) were cotransfected with p21Waf1 (0.4 Wg). Relative
promoter activity (luciferase units/L-gal activity) following transfec-
tion is shown. B: The e¡ect of p21Waf1 on transcriptional activity of
p16INK4 transfected stably with p21Waf1 and pSIR-EGFP of the pro-
moter of p16INK4. Lane 1, pDOR+pSIR-0-EGFP; lane 2, pDOR-
p21+pSIR-0-EGFP; lane 3, pDOR+pSIR-870-EGFP; lane 4,
pDOR-p21+pSIR-870-EGFP. The intensity of the reporter EGFP
was detected by £ow cytometry. C, D: The e¡ect of p21Waf1 on
protein level of p16INK4 transfected stably with pDOR-p21Waf1-sense
and pDOR-p21Waf1-antisense by Western blot analysis.
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p21Waf1 on p16INK4 expression is mediated through these GC-
boxes, we mutated two sites (3449 and 3459 bp) individually
and then in combination. Luciferase reporter constructs, con-
taining di¡erent combinations of wild-type and mutated sites,
were generated and transiently cotransfected with the p21Waf1
expression vector (Fig. 2). Mutation of the 3449 bp binding
site reduced the expression of the p16INK4-Luc reporter to the
basal level while the mutation at 3459 bp reduced the expres-
sion of the p16INK4-Luc reporter by 80^90%. It could not
promote its activities even when transfected with p21Waf1.
These results suggested that the GC-box at 3449 bp is the
key constitutive element of the p16INK4 promoter and the GC-
box at 3459 bp is also signi¢cant.
3.2. Sp1 is involved in the activation of p16INK4 promoter by
p21Waf1
The results of the p16INK4-Luc experiment showed that
p21Waf1 can activate the transcription of p16INK4, but
p21Waf1 itself is not a transcription factor and cannot bind
the p16INK4 promoter directly. To ¢nd which transcription
factor plays the most important role, we used Western blot
analysis to examine the protein level of transcription factors
Sp1, Sp3, E47 and Id1, which have been demonstrated to
participate in the transcriptional regulation [15,16]. The re-
sults showed that the expression of Sp1 increased signi¢cantly
after p21Waf1 transfection (Fig. 3A). There was no di¡erence
in the expression of Sp3 (Fig. 3A) or E47 (Fig. 3B) after
transfection with p21Waf1, while a small reduction in the ex-
pression of Id1 was found (Fig. 3C). These results suggested
that among these transcription factors, Sp1 is the key factor in
a¡ecting the activation of p16INK4 by p21Waf1. While E47^Id1
heterodimeric complex may also have an e¡ect, however, it
may not be important to this event.
3.3. Sp1 activates the expression of p16INK4-Luc and promotes
the protein level of p16INK4
To investigate whether Sp1 can activate the p16INK4 pro-
moter, an Sp1 expression vector was transfected with p16INK4-
Luc reporter in HeLa cells. The results showed that Sp1 can
activate the p16INK4 promoter and exerts its e¡ects through
the promoter region 3127 to 3620 bp (Fig. 4A, B). Trans-
fection with Sp3 expression vector showed that Sp3 acts as a
negative regulator of the p16INK4 promoter in this system
(Fig. 4A, B).
To further support the results above, mithramycin A, a
potent inhibitor of Sp1 binding to GC-box in DNA, was
added to the cells to detect whether the protein level of
p16INK4 could be decreased when the activity of Sp1 was
blocked. The result indicated that the addition of mithramycin
A to the cells led to a concentration-dependent inhibition of
the protein level of p16INK4 with 40% inhibition at 50 nM and
nearly 70% inhibition at 100 nM mithramycin A concentra-
tion (Fig. 4C, D).
3.4. Sp1 and Sp3 bind to the GC-box
Using nuclear extracts of HeLa cells with double-stranded
oligo DNA containing GC-box showed three speci¢c bands
(Fig. 5). Excess amounts of oligo DNA (speci¢c competitor)
diminished the speci¢c bands (Fig. 5, lane 3). Preincubation
with Sp1 antibodies supershifted the top band (Fig. 5, lane 4),
whereas preincubation with Sp3 antibodies diminished the
bottom band (Fig. 5, lane 5). Coincubation with Sp1 and
Sp3 antibodies supershifted the top band and diminished the
bottom band (Fig. 5, lane 6). These experiments suggested
that Sp1 and Sp3 could bind to the GC motif and activate
or inactivate p16INK4 promoter activity.
4. Discussion
p21Waf1- as well as p16INK4-mediated inhibition of CDKs
will result in non- phosphorylation of Rb. Due to this E2F
could not be released to activate a certain gene to regulate the
progression from G1 phase to S phase of the cell cycle. This is
the classic pathway. In addition, CDK inhibitors, for example
p21Waf1, can also a¡ect certain transcription factors directly to
activate or inactivate target genes [17,18]. There is much evi-
dence to support the fact that p21Waf1 is an e¡ector of
p16INK4, which is associated with a posttranscriptional induc-
tion of p21Waf1 [19]. In addition, p21Waf1-mediated inhibition
of CDK2 is a common element of the ARF/p53 and p16INK4/
pRb response pathways, as well as a potential point of coop-
eration between them. However, the question of what is the
e¡ect of p21Waf1 on p16INK4 remains. Recently, there is a
hypothesis that p21Waf1 can initiate the expression of
Fig. 2. The e¡ect of GC-box mutations on the transcriptional activ-
ity of p16INK4 promoter measured by luciferase assay. Lane 1,
pGL3-basic negative control (E 0-bp p16INK4 promoter fragment)
and positive control (F 3620-bp p16INK4 promoter fragment); lane
2, 620-bp promoter fragment with mutation within the GC-box at
position 3449 bp; lane 3, 620-bp promoter fragment with mutation
within the GC-box at position 3459 bp; lane 4, 620-bp promoter
fragment with mutation at both 3449 and 3459 bp. These were
transfected into either HeLa cells only or HeLa cells transiently
transfected with pDOR or pDOR-p21 construct.
E
Fig. 3. Western blot analysis of HeLa cells transfected stably with
pDOR-p21Waf1. A: Sp1 and Sp3, B: E47, C: Id1, and D: L-actin.
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p16INK4 [20]. How does p21Waf1 behave in this case? The aim
of this paper is to further explore the relationship between
p21Waf1 and p16INK4 at the transcription level and search
for the potential transcription factors involved in this process.
HeLa cell line, a typical cell line that has high transfection
e⁄ciency, was reported to maintain low p53 levels (from the
website of ATCC, www.atcc.org), and in this cell line the
functions of p53 and pRb were de¢cient [21]. Therefore,
p21Waf1, as the downstream target of p53 pathway, will not
be a¡ected by p53, and p16INK4 will not be regulated by pRb.
Thus this cell line is an ideal model for studying the biological
e¡ect of p21Waf1 expression on p16INK4.
The complexity of tissue- or stage-speci¢c gene regulation
normally results from well-de¢ned interactions between the
promoter and the transcription factors. The promoter region
of a gene contains multiple binding sites for transactivators.
Some elements, like the E-box, GC-box and AP-1-like site,
which are all the binding sites of E-proteins, Sp family pro-
teins and the transcription factor JunB respectively, are dis-
tributed in the p16INK4 promoter. The transactivation e¡ect of
Fig. 4. Transcriptional activities of the p16INK4 promoter deletions with Sp1 or Sp3. A: The di¡erent p16INK4 promoter pGL3-Luc constructs
(0.4 Wg) were cotransfected with 0.4 Wg of pCMV-Sp1, pCMV-Sp3 or pCMV only as control, and 0.2 Wg of pSV-L-gal. The luciferase and
L-gal activity values were determined. B: Various doses of the pCMV-Sp1 or pCMV-Sp3 (0, 0.2, 0.4, 0.8 Wg) were cotransfected with 0.2 Wg of
pGL3-Luc constructs. Luciferase and L-gal activity values were determined. C, D: The e¡ect of Sp1 on protein level of p16INK4 in HeLa cells
treated with mithramycin A by Western blot analysis.
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p21Waf1 on the p16INK4 promoter raises the question which
transcription factor makes the most signi¢cant contribution
to the event.
Among these transcription factors, Sp1 can stimulate the
transcription not only from proximal promoters, but also
from distal enhancers [22]. Although Sp3 was found to be
highly homologous to Sp1 with similar a⁄nities for GC-
and GT-boxes, there are some striking functional di¡erences
between them. In some cell lines, it can activate transcription
[23^26]. However, under other circumstances Sp3 is only
weakly active, and in some cases Sp3 can repress transcription
driving by Sp1 or other transcription factors [27^29]. In this
research, the e¡ect of the expression of Sp1 upregulated by
p21Waf1 may be relevant to the mitogen-activated protein/
extracellular signal-regulated kinase pathway, as well as other
potential mechanisms. It was reported that the phosphoryla-
tion of Sp1 in known mitogen-activated protein kinase resi-
dues (threonine 453 and 739) was promoted, when operated
with agents that could arrest the cell cycle, thereby leading to
an Sp1 binding increase and transcription enhancement [30].
In addition, expression of Sp1 can be increased by low con-
centrations of CDK inhibitors such as UCN-01 (the chemical
inhibitor) and overexpression of p21Waf1 by increasing the
levels of Sp1 mRNA [17]. The e¡ects that Sp1 activates
p16INK4 were further conformed using mithramycin A, an
inhibitor of Sp1 binding, other than the luciferase assay.
The e¡ect of activation on p16INK4 promoter is dependent
on the integrity of the regulating sequences, such as the region
3449 to 3459 bp where Sp1/Sp3 bind to in p16INK4 pro-
moter, the mutation within this region caused the opposite
e¡ect, as a new negative element may be formed or the spatial
structure could be changed, which could then alter the combi-
nation between the transcription factor and the element.
Although Sp3 acts as a suppressor of p16INK4, its level is
not signi¢cantly a¡ected by p21Waf1.
E47 belongs to the basic helix-loop-helix (bHLH) family of
proteins. It could bind DNA as homodimers or as hetero-
dimers with the class B or tissue-speci¢c bHLH transcription
factors and activate transcription of target genes that contain
the E-box motif CANNTG in their promoter [31]. Id1, a
member of Id HLH protein family, acts by associating with
bHLH transcription factors, such as E47, preventing these
factors from forming functional hetero- or homodimeric
DNA binding complexes; thus suppressing the activation of
transcription induced by E-proteins. We have shown that
p21Waf1 expression has no signi¢cant e¡ect on E47 and only
leads to a slight decrease of Id1. This indicates that E47^Id1 is
not the major e¡ector in the activation of p16INK4 transcrip-
tion induced by p21Waf1.
Recently, great progress has been made in the understand-
ing of transcriptional regulation of di¡erent CDK inhibitors.
However, most studies have focused on the roles of the ele-
ment of the promoter and transcription factors in individual
CDK inhibitors. The interactions between them have rarely
been reported. This study begins to unravel the complex rela-
tionships between two of the most important negative regu-
lators of the cell cycle, p16INK4 and p21Waf1, at the level of
transcriptional regulation. This knowledge is needed to fully
understand cell cycle progression, as well as the mechanisms
of tumorigenesis and senescence. Nevertheless, further work
should be carried out, in normal and other cell lines, to in-
crease general information from multiple perspectives.
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